Company: IPSC
Filing Date: 2025-07-10
Form Type: S-3
Source: 0001104659-25-067022
Chunk: 43

Company: Century Therapeutics, Inc.
Filing Date: 2025-07-10
Form: S-3
Chunk 43
---
SPECTUS Item 14. Other Expenses of Issuance and Distribution. The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby, other than the SEC registration fee.

| ​ | SEC registration fee                                     | ​ | ​ | ​ | $ | 0* | ​ | ​ |
| ​ | The Nasdaq Global Select Market supplemental listing fee | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Fees and expenses of the trustee                         | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Printing expenses                                        | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Legal fees and expenses                                  | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Accounting fees and expenses                             | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Blue Sky, qualification fees and expenses                | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Transfer agent fees and expenses                         | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Miscellaneous                                            | ​ | ​ | ​ | $ | -1 | ​ | ​ |
| ​ | Total                                                    | ​ | ​ | ​ | $ | -1 | ​ | ​ |

* The registrant is filing this registration statement to replace its existing registration statement (No. 333-265975), which is expiring pursuant to Rule 415(a)(5). In accordance with Rule 415(a)(6), effectiveness of this registration statement will be deemed to terminate such prior registration statement. The filing fee associated with this registration statement was carried forward from our prior registration statement, and no additional filing fee is due in connection with the filing of this registration statement. Please see the registration fee table contained in Exhibit 107 to this registration statement for more information (1) These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. Item 15. Indemnification of Directors and Officers. As permitted by Section 102 of the DGCL, the Company’s Certificate of Incorporation and amended and restated bylaws limit or eliminate the personal liability of the Company’s directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care